Compass Therapeutics Investor Relations Material

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics primarily targeting oncology. The company’s research centers on the interaction between angiogenesis, the immune system, and tumor growth. Its pipeline includes novel therapeutic candidates designed to modulate key biological pathways to elicit an effective anti-tumor response. This includes strategies to influence the tumor microvasculature, activate immune cells, and overcome immunosuppressive mechanisms employed by tumors. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.